Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon.
Despite being free of charge, treatment adherence to 7-day primaquine for the radical cure of Plasmodium vivax was estimated at 62.2% among patients along the Iquitos-Nauta road in the Peruvian Amazon. The principal reason for non-adherence was the perceived adverse effects related to local humoral illness conceptions that hold that malaria produces a hot state of body, which is further aggravated by the characteristically hot medical treatment. Notably, patients were willing to adhere to the first 3 days of treatment during which symptoms are most apparent and include the characteristic chills. Nevertheless, as symptoms abate, the perceived aggravating characteristics of the medication outweigh the perceived advantages of treatment adherence. Improving community awareness about the role of primaquine to prevent further malaria transmission and fostering a realistic system of direct observed treatment intake, organized at community level, can be expected to improve adherence to the radical cure of P. vivax in this area.
Grietens
Koen Peeters
KP
Department of Parasitology, Institute of Tropical Medicine, Antwerp, Belgium. kpeeters@itg.be
Soto
Veronica
V
Erhart
Annette
A
Ribera
Joan Muela
JM
Toomer
Elizabeth
E
Tenorio
Alex
A
Montalvo
Tanilu Grande
TG
Rodriguez
Hugo
H
Cuentas
Alejandro Llanos
AL
D'Alessandro
Umberto
U
Gamboa
Dionicia
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003466:Cultural Characteristics; D023801:Directly Observed Therapy; D006801:Humans; D007223:Infant; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D008875:Middle Aged; D010349:Patient Compliance / Q000523:psychology; D010568:Peru / Q000453:epidemiology; D010966:Plasmodium vivax / Q000187:drug effects; D011319:Primaquine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
D000962:Antimalarials; D011319:Primaquine